Clinical Trial Update: Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating the combination of acalabrutinib and rituximab for previously untreated mantle cell lymphoma and is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING